How Repatha Cut Deaths by 20 Percent Before Any Heart Attack
Why did a cholesterol drug take a year and a half to start saving lives, and why did people without any visible plaque benefit just as much as those with confirmed disease?
Dr. Alo and Hannah break down the VESALIUS-CV mortality data, a rare cholesterol trial that measured actual deaths instead of just heart attacks and strokes, in people who had never had either. They cover the twenty percent drop in all-cause mortality, why the benefit only appeared after eighteen months, and what this means for anyone with plaque or high-risk diabetes still sitting on a borderline LDL.
Read the full post: https://dralo.net/blog/vesalius-repatha-all-cause-mortality
Questions this episode answers:
Why did the cholesterol drug take so long to reduce deaths?
What is the VESALIUS-CV trial and what did it find?
Does evolocumab reduce mortality in people without a prior heart attack?
Should I stop my cholesterol medication if I feel no difference?
What is apoB testing and why does it matter more than LDL?
Does PCSK9 inhibitor therapy help people with diabetes but no visible plaque?
Keywords: repatha, evolocumab, vesalius cv trial, pcsk9 inhibitor, ldl cholesterol, apob testing, cardiovascular mortality, atherosclerosis, statin therapy, heart attack prevention, cholesterol lowering drugs, primary prevention cardiology
This episode is for education only and is not medical advice. Talk to your own clinician about your own situation.
#heart #cardiology #drAlo #cholesterol #pcsk9 #ldl #heartdisease
